MTN 003B

Bone Mineral Density Substudy to MTN 003 (VOICE)

US National Institute of Allergy and Infectious Diseases (NIAID)
Division of AIDS (DAIDS)
US National Institutes of Health (NIH)

Protocol Summary:
MTN 003B is a substudy of MTN 003 (VOICE), which will compare changes in bone mineral density (BMD) after one year among VOICE participants receiving oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)/TDF compared with oral placebo.

Years: 2009 – 2014

Z.M. Chirenje, MD, FRCOG
Tsitsi Magure, MBChB, MMed

Locations: Spilhaus, Seke South, and Zengeza CRSs


Completed Study


Mgodi NM, Kelly C, Gati B, et al. Factors Associated with Bone Mineral Density in Health African Women. Arch Osteoporos. 2015;10:206.

Mirembe BG, Kelly CW, Mgodi N, et al. Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):287-94.

Comments are closed.